Roche Holding AG (OTCMKTS:RHHBY) Shares Purchased by Altrius Capital Management Inc

Altrius Capital Management Inc boosted its position in shares of Roche Holding AG (OTCMKTS:RHHBY) by 0.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 183,448 shares of the company’s stock after buying an additional 603 shares during the period. Roche accounts for approximately 1.7% of Altrius Capital Management Inc’s portfolio, making the stock its 23rd biggest holding. Altrius Capital Management Inc’s holdings in Roche were worth $6,399,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kornitzer Capital Management Inc. KS raised its position in Roche by 1.3% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company’s stock valued at $5,490,000 after purchasing an additional 1,798 shares during the last quarter. Verity Asset Management Inc. acquired a new position in shares of Roche during the 3rd quarter worth $253,000. Canopy Partners LLC increased its holdings in shares of Roche by 4.6% in the 3rd quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after purchasing an additional 344 shares in the last quarter. Brooklyn Investment Group acquired a new stake in shares of Roche in the third quarter valued at about $40,000. Finally, IHT Wealth Management LLC purchased a new stake in Roche during the third quarter worth about $236,000.

Roche Price Performance

Shares of OTCMKTS RHHBY opened at $41.44 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. The company has a 50-day moving average of $38.09 and a two-hundred day moving average of $38.42. Roche Holding AG has a 1-year low of $29.20 and a 1-year high of $42.43.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. UBS Group upgraded shares of Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Morgan Stanley began coverage on Roche in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.